Federal Register Notice: FDA has determined the regulatory review period for MELA Sciences Inc.’s Melafind System is 3,837 days for the extension of a patent that claims that medical device. Melafind System is indicated for use on clinically atypical cutaneous pigmented lesions with one or more clinical or historical characteristics of melanoma, excluding those with a clinical diagnosis of melanoma or likely melanoma. To view this notice, click here.
